| Bioactivity | Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research[1]. |
| Invitro | Neihulizumab 是一种针对 P-选择素糖蛋白配体-1 (PSGL-1) 的单克隆抗体。Neihulizumab 与人 PSGL-1 结合，从而优先诱导晚期活化 T 细胞的凋亡。在炎症部位，血管内皮表达 P-选择素，活化的 T 细胞与这些部位结合并通过 PSGL-1 的表达迁移。以这种方式，Neihulizumab 被认为靶向活化的 T 细胞并抑制运输到发炎组织部位[1]。 |
| Name | Neihulizumab |
| CAS | 2158362-38-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |